M. Ezekowitz

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

S. Yusuf, Á. Avezum, J. Douketis, 2012, Circulation.

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.

S. Yusuf, S. Hohnloser, M. Böhm, 2020, European heart journal.

Drug Interactions Affecting Antiarrhythmic Drug Use

Philip L. Mar, M. Chung, P. Noseworthy, 2022, Circulation. Arrhythmia and electrophysiology.

Stroke Prevention in Atrial Fibrillation II Study

S. Connolly, M. Ezekowitz, R. Mcbride, 1994, The Lancet.

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

G. Lip, J. Douketis, J. Healey, 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Demonstration of TrialTracker: A Customizable Database for Managing Administrative Data for Clinical Trials

Perry L. Miller, Sandra J. Frawley, Charles Lu, 1999, AMIA.

Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.

H. Heidbuchel, S. Yusuf, Á. Avezum, 2013, Circulation.

The use of dabigatran according to body mass index : the RE-LY experience

S. Yusuf, S. Connolly, H. Parise, 2014 .

Antithrombotic agents in coronary artery disease.

J. Cairns, P. Théroux, G. Sutton, 1995, Chest.